Strong First Quarter for Nycomed Amersham

Apr 23, 2001, 01:00 ET from Nycomed Amersham plc

    LONDON, April 23 /PRNewswire/ -- In the first of a series of releases
 planned to keep the market up to date with trading on a quarterly basis,
 Nycomed Amersham plc (NYSE:   NYE), (LSE: NAM) today reported details of its
 sales performance in the first three months of 2001.
     The group as a whole enjoyed a strong first quarter with sales of
 375m pounds sterling (2000: 299m pounds) representing growth at constant
 exchange rates of 16 per cent.
     All parts of the Imaging business, Nycomed Amersham Imaging, performed in
 line with or ahead of the company's expectations.  First quarter sales
 amounted to 221m pounds (178m pounds).  This represented an increase of
 13 per cent at constant exchange rates for the continuing businesses, against
 a slower start in 2000.  Sales of the portfolio of patented diagnostic
 products targeted principally at the cardiovascular, neurological and oncology
 areas grew at 25 per cent. Particularly good growth was recorded by
 X-ray contrast media products in Europe and the United States.
     At the beginning of April, Nycomed Amersham Imaging won an extension to
 its contract to supply Novation, the United States' largest healthcare supply
 company, until 31 March 2005.  The contract covers Nycomed Amersham Imaging's
 full line of X-ray and MRI contrast media products.
     The Life Sciences business, Amersham Pharmacia Biotech, achieved sales of
 154m pounds (121m pounds), representing growth of 21 per cent at constant
 exchange rates.  This growth rate was slightly higher than usual as a result
 of sales delayed from the end of last year, and a favourable comparison with a
 weaker first quarter in 2000.  Second quarter sales in Life Sciences will be
 compared with the stronger second quarter results of 2000.
     Drug Discovery benefited from growth in proteomics and in new geographical
 markets which compensated for some weakening in the North American market.
 Separations continued to perform strongly, reflecting the ongoing growth in
 biopharmaceutical manufacturing.  Laboratory products returned to modest
 growth.
     Commented Sir William Castell, Chief Executive, Nycomed Amersham plc "We
 have made an excellent start to 2001 with good underlying rates of growth.
 Our first quarter demonstrates not only strong growth in diagnostic imaging
 markets worldwide, but also the benefits of our own geographical diversity.
 There were particularly strong performances from our Life Sciences business in
 Japan and other international markets, and from our Imaging business in North
 America".
 
     Nycomed Amersham plc is a world leader in in-vivo diagnostic imaging and
 life sciences. Based in the United Kingdom, the company has annual sales of
 1.4 billion pounds (approximately U.S. $2.1 billion) and around
 8,900 employees worldwide.
 
 

SOURCE Nycomed Amersham plc
    LONDON, April 23 /PRNewswire/ -- In the first of a series of releases
 planned to keep the market up to date with trading on a quarterly basis,
 Nycomed Amersham plc (NYSE:   NYE), (LSE: NAM) today reported details of its
 sales performance in the first three months of 2001.
     The group as a whole enjoyed a strong first quarter with sales of
 375m pounds sterling (2000: 299m pounds) representing growth at constant
 exchange rates of 16 per cent.
     All parts of the Imaging business, Nycomed Amersham Imaging, performed in
 line with or ahead of the company's expectations.  First quarter sales
 amounted to 221m pounds (178m pounds).  This represented an increase of
 13 per cent at constant exchange rates for the continuing businesses, against
 a slower start in 2000.  Sales of the portfolio of patented diagnostic
 products targeted principally at the cardiovascular, neurological and oncology
 areas grew at 25 per cent. Particularly good growth was recorded by
 X-ray contrast media products in Europe and the United States.
     At the beginning of April, Nycomed Amersham Imaging won an extension to
 its contract to supply Novation, the United States' largest healthcare supply
 company, until 31 March 2005.  The contract covers Nycomed Amersham Imaging's
 full line of X-ray and MRI contrast media products.
     The Life Sciences business, Amersham Pharmacia Biotech, achieved sales of
 154m pounds (121m pounds), representing growth of 21 per cent at constant
 exchange rates.  This growth rate was slightly higher than usual as a result
 of sales delayed from the end of last year, and a favourable comparison with a
 weaker first quarter in 2000.  Second quarter sales in Life Sciences will be
 compared with the stronger second quarter results of 2000.
     Drug Discovery benefited from growth in proteomics and in new geographical
 markets which compensated for some weakening in the North American market.
 Separations continued to perform strongly, reflecting the ongoing growth in
 biopharmaceutical manufacturing.  Laboratory products returned to modest
 growth.
     Commented Sir William Castell, Chief Executive, Nycomed Amersham plc "We
 have made an excellent start to 2001 with good underlying rates of growth.
 Our first quarter demonstrates not only strong growth in diagnostic imaging
 markets worldwide, but also the benefits of our own geographical diversity.
 There were particularly strong performances from our Life Sciences business in
 Japan and other international markets, and from our Imaging business in North
 America".
 
     Nycomed Amersham plc is a world leader in in-vivo diagnostic imaging and
 life sciences. Based in the United Kingdom, the company has annual sales of
 1.4 billion pounds (approximately U.S. $2.1 billion) and around
 8,900 employees worldwide.
 
 SOURCE  Nycomed Amersham plc